Jorge Rodrigo, Costa Rogério A, Calucci Daniela, Scott Ingrid U
Department of Ophthalmology, Ribeirão Preto School of Medicine, University of São Paulo, Ribeirão Preto, SP, Brazil.
Graefes Arch Clin Exp Ophthalmol. 2007 Jul;245(7):1045-8. doi: 10.1007/s00417-006-0468-2. Epub 2006 Nov 29.
To describe the clinical, angiographic, and optical coherence tomography findings of a patient with subretinal neovascularization (SRN) in idiopathic juxtafoveolar retinal telangiectasis (IJRT) treated with intravitreal bevacizumab injection.
In the setting of a tertiary referral center, a patient with bilateral acquired IJRT, complicated with juxtafoveal SRN in one eye, was treated with a single intravitreal injection of 1.5 mg of bevacizumab and then prospectively followed for 24 weeks.
Vision improved from 20/40(-1) to 20/20(-2) by 24 weeks of follow-up. Fluorescein angiography demonstrated the absence of leakage from a previously active SRN. Optical coherence tomography revealed gradual neovascular lesion contraction and the resolution of subretinal fluid over the 24-week follow-up period. No obvious adverse events were noted.
In the short-term, intravitreal bevacizumab treatment resulted in partial restoration of the macular architecture and vision improvement by means of neovascular lesion regression and the resolution of associated serohemorrhagic complications.
描述玻璃体内注射贝伐单抗治疗特发性黄斑旁视网膜毛细血管扩张症（IJRT）合并视网膜下新生血管（SRN）患者的临床、血管造影及光学相干断层扫描结果。
在一家三级转诊中心，一名双侧获得性IJRT患者，其中一只眼睛合并黄斑旁SRN，接受了一次玻璃体内注射1.5毫克贝伐单抗治疗，随后进行了24周的前瞻性随访。
随访24周时，视力从20/40（-1）提高到20/20（-2）。荧光素血管造影显示先前活跃的SRN无渗漏。光学相干断层扫描显示在24周的随访期内，新生血管病变逐渐收缩，视网膜下液消退。未观察到明显不良事件。
短期内，玻璃体内注射贝伐单抗治疗通过新生血管病变消退和相关血清出血性并发症的消退，导致黄斑结构部分恢复和视力改善。
